Drag a card by its title · ⚙ to size, swap or remove

The company

Kymera Therapeutics, Inc.

KYMR · Nasdaq

Health CareBiotechnologyLeading

KYMR stood above a rising 150-day average in 51 of the last 52 weekly readings, including each of the last 19 weeks. It is 5.4% above that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

SEC filings

Statistics

Rotation: Leading
Weeks in an uptrend: 19 in a row
Industry in uptrend: 15% -17 in 4 wk
Insider buys, 12 months: $172.5M
Insider sales, 12 months: $904.9M
Officials’ trades on record: 0
Institutions holding: 259 (+21)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 51 of 52 weeks.

17 Apr – 16 Oct

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months1

Sale orders, 12 months62

Buyers · sellers1 · 12

Who	Did	Shares	Traded
Nello MainolfiChief Executive Officer	sold	3,525at $111.44	1 Oct 2026filed 1 Oct 2026
Nello MainolfiChief Executive Officer	sold	5,506at $112.42	1 Oct 2026filed 1 Oct 2026
Nello MainolfiChief Executive Officer	sold	4,876at $113.24	1 Oct 2026filed 1 Oct 2026
Nello MainolfiChief Executive Officer	sold	7,601at $114.43	1 Oct 2026filed 1 Oct 2026
Nello MainolfiChief Executive Officer	sold	8,230at $115.40	1 Oct 2026filed 1 Oct 2026
Nello MainolfiChief Executive Officer	sold	262at $116.12	1 Oct 2026filed 1 Oct 2026
Brian AdamsChief Legal Officer	sold	1,209at $115.55	4 Sep 2026filed 4 Sep 2026
Brian AdamsChief Legal Officer	sold	3,025at $116.81	4 Sep 2026filed 4 Sep 2026
Brian AdamsChief Legal Officer	sold	2,137at $117.57	4 Sep 2026filed 4 Sep 2026
Nello MainolfiChief Executive Officer	sold	50,000at $119.00	7 Jul 2026filed 7 Jul 2026
Nello MainolfiChief Executive Officer	sold	1,883at $112.80	1 Jul 2026filed 2 Jul 2026
Nello MainolfiChief Executive Officer	sold	6,626at $113.98	1 Jul 2026filed 2 Jul 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders259+21 on the quarter

New · exited49 · 28

Reported value$9.6B

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

Manager	Shares	Change
FMR LLCadded · filed 13 Aug 2026	12,349,256$1.4B	+649,306+5.5%
BAKER BROS. ADVISORS LPunchanged · filed 14 Aug 2026	8,657,242$992.7M	00.0%
Avoro Capital Advisors LLCunchanged · filed 14 Aug 2026	7,474,747$857.1M	00.0%
BlackRock, Inc.added · filed 7 Aug 2026	5,538,210$635.1M	+477,334+9.4%
BVF INCreduced · filed 14 Aug 2026	3,872,052$444.0M	-1,630,658−29.6%
WELLINGTON MANAGEMENT GROUP LLPreduced · filed 14 Aug 2026	3,675,028$421.4M	-214,659−5.5%
VANGUARD PORTFOLIO MANAGEMENT LLCadded · filed 13 Aug 2026	2,992,193$343.1M	+118,137+4.1%
Siren, L.L.C.reduced · filed 13 Aug 2026	2,935,830$336.7M	-251,000−7.9%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026	2,932,378$336.3M	+52,054+1.8%
Atlas Venture Life Science Advisors, LLCreduced · filed 13 Aug 2026	2,847,541$326.5M	-1,730,467−37.8%